Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer Cohort

15 Jul 2024

Abstract excerpt

PURPOSE: Immunotherapy (IO) in triple-negative breast cancer (TNBC) has improved survival outcomes, with promising improvements in pCR rates among early high-risk hormone receptor (HR)+/HER2- breast cancers. However, biomarkers are needed to select patients likely to benefit from IO. MHC-I and tumor-specific MHC-II (tsMHC-II) expression are candidate biomarkers for PD-(L)1 checkpoint inhibition but existing data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Immunotherapy and Biomarkers
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39007881
DOI: 10.1158/1078-0432.ccr-24-1286

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Associations of Immune Checkpoint Predictive Biomarkers (MHC-I and MHC-II) with Clinical and Molecular Features in a Diverse Breast Cancer CohortPMID 39007881Read ↗

Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor BehaviorSemantic proximity Read ↗

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.Semantic proximity Read ↗

Exploring Racial Differences in Pathological Complete Response to Neoadjuvant Chemotherapy and Pembrolizumab in Triple-Negative Breast CancerSemantic proximity Read ↗

Computational analysis of the functional impact of MHC-II-expressing triple-negative breast cancerSemantic proximity Read ↗

Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell ExhaustionSemantic proximity Read ↗

MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor–positive HER2-negative breast cancerSemantic proximity Read ↗

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.Semantic proximity Read ↗

The MHCII Immune Activation Score predicts risk of recurrence and benefit of taxanes in Basal-like and HER2-enriched breast cancerSemantic proximity Read ↗

The impact of patient biology on racial disparities in breast cancer outcomeSemantic proximity Read ↗

Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast CancerSemantic proximity Read ↗

MHC class I and class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanomaSemantic proximity Read ↗

Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.